Gilead’s overpriced hepatitis C treatment Sovaldi (Sofosbuvir), with sales of$8.5 billion in Q1-Q3 2014, has become a veritable star product in 2014. At this time, there are new developments for this star product. According to the Clove Insight – China Pharma Data database, Sofosbuvir tablets were declared clinical in August 2013, and the application has now left the Supplementary Information Task Sequence and was approved on December 26, 2014, with Gilead about to get the clinical approval for the drug in China after waiting more than a year. The hepatitis C star drug, which has a cure rate of more than 80%, is one step closer to Chinese patients, except that Gilead’s list of 91 developing countries worldwide to which Sovaldi is sold at 1% of the U.S. market price does not include China. The domestic declaration of Sofosbuvir by Sichuan Kolon, Jiangsu Haosen, Zhengda Tianqing, Shih Pharmaceutical Group and other companies are still continuing the long wait, not to mention that domestic companies must also wait for the long patent period of the original product, or solve the patent issue before they can benefit from patients on the market. Meanwhile, Gilead’s Ledipasvir/Sofosbuvir fixed-dose combination tablet has advanced 73 spots in the IND review sequence since the end of September and is now ranked 310th, pending the start of professional review. Hepatitis C treatment breakthroughs: who’s hurting and who’s reveling.